Role of Ranibizumab in macular edema due to branch retinal vein occlusion by Shorya Vardhan, Azad
 ROLE OF RANIBIZUMAB IN MACULAR EDEMA DUE 
TO BRANCH RETINAL VEIN OCCLUSION 
 
 
Dissertation  submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI, INDIA 
 
 
 
M.S.DEGREE EXAMINATION 
BRANCH – III OPHTHALMOLOGY 
 
MARCH 2011 
 
  
 
This is to certify that the dissertation entitled “ROLE OF RANIBIZUMAB IN MACULAR 
EDEMA DUE TO BRANCH RETINAL VEIN OCCLUSION” is a bonafide work done by Dr. 
SHORYA VARDHAN AZAD, Postgraduate student in M.S. (Ophthalmology) during MARCH 2009 
to MARCH 2011, under our direct supervision and guidance, at our institute, in partial fufillment for the 
award of M.S. Degree in Ophthalmology of  the Tamilnadu Dr. M.G.R. Medical University, Chennai. 
 
 
 
 
Dr. Amjad Salman,       Dr.  M. Rajamohan,  
M.S        M.S., D.O.M.S., C.C.E.H. (London)             
Professor  of  Ophthalmology     Professor  of  Ophthalmology 
Guide        Co guide 
 
 
Dr. C.A.Nelson Jesudasan, 
M.S., D.O.M.S., FRCS (Edin. & Glas.)   
Professor and Director 
 
 
  
 
ACKNOWLEDGEMENT 
 
 
 
I would like to express my profound gratitude to Professor and Director, 
Dr.C.A.Nelson Jesudasan, M.S., D.O.M.S., FRCS (Edin, & Glas.) for having 
assigned me this very interesting topic, for providing me all the necessary 
facilities and guidance to enable me to complete my study. 
 
I am really indebted to Prof. Dr. Amjad Salman, M.S., Registrar for being 
my guide in this study. His corrections and criticism molded every step in this 
study. 
 
  I would like to thank Prof. Dr. M. Rajamohan, M.S., D.O.M.S., 
C.C.E.H. (London), who was the co-guide for the study. I express my gratitude 
to his customary patience and guidance taken in clarifying my various doubts 
and rendering his valuable advice. 
 
         I am also grateful to Prof. Dr. Philip Aloysius Thomas, M.D., PhD. 
(Microbiology) for his guidance and inspiration throughout this study and for 
extending technical guidance and support. 
 
 
          I would like to thank my father Prof. Dr. Raj Vardhan Azad, M.D., 
FRCS (Edin), and mother Mrs. Sheela Azad for their moral support and 
prayers. 
 
          I would also like to thank my wife Dr Shikha Azad for her inspiration 
and moral support. 
 
          I also thank all my teachers, my colleagues, especially Dr. Rameez 
Hussain, Dr. Vinod Nathaniel, Dr. Achyut Pandey, and Mr. John Rice 
(Technician),  Ms. P. Renuga Devi (Nursing),  Mr. Subramani (M.R.D.),  
Mr. Koil Pillai (M.R.D.), Mr. Daniel Prince and Mr. Rajkumar for their 
timely help and technical assistance throughout the study. 
 
Finally I am indebted to all my patients for their sincere co-operation for the 
completion of the study. 
 
 
  
 
CONTENTS 
 
1. INTRODUCTION                                                                1 
2. AIM OF THE STUDY                                                          4 
3. REVIEW OF LITERATURE                                                5 
4. MATERIALS AND METHODS                                           30 
5. RESULTS                                                                          37 
6. DISCUSSION                                                                    48 
7. CONCLUSION                                                                  52 
8. SUMMARY                                                                        53 
 
BIBLIOGRAPHY 
PROFORMA 
 
1 
 
 
INTRODUCTION 
 
           Retinal vein occlusion (RVO) is the second most common cause of retinal vascular 
disease after diabetic retinopathy1,2. Previous studies have reported the prevalence of RVO 
3,4,5. In the population-based Blue Mountains Eye Study (Australia), the prevalence of retinal 
vein occlusion was 1.6%. In the Framingham Eye Study (USA), of the 2,631 persons who 
underwent a screening examination, 4 of the 156 eyes found  to have retinopathy had a retinal 
vein occlusion. The Beaver Dam Study (USA) reported a prevalence of 0.6% in patients older 
than 43 years.  
 
              The incidence of  RVO is estimated 180 000 eyes per year in United States, and 
branch retinal vein occlusion is the more common of the two presentations, accounting for 
approximately 80% of RVO5,6. Macular edema is one of the leading cause of vision loss in  
patients with either central or branch retinal vein occlusions (CRVO or BRVO)7. This  edema 
is found to be due to hypoxia-induced up regulation of  vascular endothelial growth 
factor(VEGF) that loosens endothelial tight junctions leading to increase in vascular 
permeability and deposition of exudative material8,9. There have been various attempts to 
reduce macular edema such as macular grid photocoagulation, intravitreal injections of  
triamcinolone acetonide or bevacizumab , but the definitive treatment modality is yet to 
emerge10,11,12,13,14.  
 
2 
 
 
 
The Collaborative Branch Vein Occlusion Study , a multi-center randomized clinical trial 
supported by the National Eye Institute, reported that argon laser photocoagulation may  
reduce visual loss from macular edema for those eyes that meet study eligibility criteria and 
are treated according to that protocol10. 
 
             Recently, there has been interest in the use of vascular endothelial growth factor 
(VEGF) inhibition in the treatment of BRVO because of the observation of increased VEGF 
in the vitreous and aqueous of patients with these conditions15.Two  trials assessed the 
efficacy and safety of intravitreat ranibizumab (Lucentis, Genentech) in BRVO16,17. The 
results have suggested that with intensive, monthly treatment, patients achieve very good 
results, superior to anything previously seen with other treatment modalities. Ranibizumab is 
a humanized anti–vascular endothelial growth factor monoclonal antibody fragment that has 
been shown to halt the growth of choroidal neovascularization(CNV) lesion and reduce 
vascular leakage. This anti-VEGF effect of ranibizumab also might be effective for treatment 
of macular edema in patients with BRVO. In one of the clinical trial, patients with macular 
edema due to BRVO were given either of two doses of ranibizumab , on average, had 
clinically and statistically significant  improvements in best corrected visual acuity (BCVA) 
compared with patients receiving sham injections. 
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   However, only a few studies have been done thus far regarding the use of of intravitreal 
ranibizumab  in macular edema due to BRVO. Moreover, no prospective study has been done 
on Indian patients regarding use of intravitreal ranibizumab in macular edema due to BRVO. 
Also, no studies have so far studied the combination therapy of anti VEGF agents  namely 
ranibizumab and bevacizumab with laser in cases with macular edema due to BRVO. 
 
      Hence this study will evaluate the anatomical and functional efficacy of intravitreal  
Ranibizumab  and intravitreal  Bevacizumab with standard laser treatment  in patients 
suffering from  macular edema due to BRVO  in a prospective manner.  
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AIM OF THE STUDY 
 
Primary Objectives 
y To study  the efficacy of  ranibizumab 0.5 mg in management of macular edema due 
to BRVO in terms of mean change from baseline in best corrected visual 
acuity(BCVA) over a  6 month treatment period. 
 
Secondary Objectives 
y To study the efficacy of ranibizumab 0.5 mg in reducing intraretinal thickness 
changes on Optical Coherence Tomography (OCT) in eyes with macular edema due 
to BRVO . 
y To compare the results obtained with ranibizumab therapy with those obtained with 
other modalities of treatment such as Laser photocoagulation and intavitreal 
Bevacizumab . 
y To study ocular and systemic safety of intravitreal ranibizumab in eyes with macular 
edema due to BRVO. 
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REVIEW OF LITERATURE 
 
             Branch retinal vein occlusion (BRVO) is a common cause of retinal vascular 
disease10. It affects males and females equally and occurs most frequently between the ages 
of 60 and 70. The interruption of venous flow in these eyes almost always occurs at a retinal 
arteriovenous intersection, where a retinal artery crosses a retinal  vein18,19.An increased risk 
of BRVO has been suggested in persons with a history of systemic hypertension, diabetes, 
hyperlipidemia, glaucoma, smoking and age related atherosclerosis20.Anti-phospholipid 
antibodies, elevated plasma homocysteine levels, and low serum folate levels have also been 
associated with increased risk of vein occlusion21,22,23. In one study a decreased risk of BRVO 
was present in individuals with higher serum levels of high density lipoprotein (HDL) and 
greater alcohol consumption20. Other studies have suggested an increased risk of BRVO in 
eyes with shorter axial lengths24,25,26,27. 
 
Clinical Features 
 
          Branch retinal vein occlusion is almost always of sudden onset; the patient presents 
with blurred vision or field defect and segmentally distributed intraretinal hemorrhage. 
Generally, intraretinal hemorrhage is less marked if the occlusion is perfused or nonischemic 
and is much more marked if the occlusion is nonperfused or ischemic and associated with 
retinal capillary nonperfusion.  
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         The location of a branch venous block determines the distribution of the intraretinal 
hemorrhage; if the venous obstruction is at the optic nerve head, two quadrants of the fundus 
may be involved, whereas if the occlusion is peripheral to the disc, one quadrant or less may 
be involved with the intraretinal hemorrhage. If the venous blockage is peripheral to tributary 
veins draining the macula, there may be no macular involvement and no decrease in visual 
acuity.  Rarely, a patient initially may present with very little intraretinal hemorrhage, which 
then becomes more extensive in succeeding weeks to months. In these instances it is pre-
sumed that an incomplete blockade at  the arteriovenous crossing has progressed to more 
complete occlusion. 
 
       One year or more after a BRVO has occurred, the intraretinal  hemorrhage may have 
completely  reabsorbed. Without the characteristic segmental distribution of intraretinal  
hemorrhage, the ophthalmoscopic diagnosis may be more difficult, but the segmental 
distribution of vascular abnormalities during the acute phase will persist and be apparent on 
fluorescein angiography. 
 
Pathogenesis 
 
       Because BRVO almost occurs at arteriovenous crossings18,19, underlying arterial 
disease may play a causative role. In 99% of 106 eyes with BRVO, the artery was located 
anterior to the vein at the obstructed site18. Histopathologically, the retinal artery and vein  
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share a common adventitial sheath, and in some cases, a common medium27. The lumen of 
the vein may be compressed up to 33% at the crossing site28,29. The vitreous may also play a 
role in compression of susceptible arteriovenous crossing sites as evidenced by studies 
demonstrating that eyes with decreased axial length and higher likelihood of vitreomacular 
attachment at the arteriovenous crossing are at increased risk of BRVO25,30. Some have 
postulated that turbulent blood flow at the crossing site causes focal swelling of the 
endothelium and deeper vein wall tissue leading to venous obstruction27,30,31. Other reports 
have demonstrated actual venous thrombus formation at the point of occlusion29,32. 
 
       The resulting venous obstruction leads to elevation of venous pressure that may 
overload the collateral drainage capacity33 and lead to macular edema and ischemia by 
mechanisms that are still under investigation. Unrelieved venous pressure can also result in 
rupture of the vein wall with intraretinal hemorrhage27. 
 
      Recently, macular edema is found to be due to hypoxia-induced up regulation of  
vascular endothelial growth factor(VEGF) that loosens endothelial tight junctions leading to 
increase in vascular permeability and deposition of exudative material8,9. 
 
Vision limiting complications 
 
     There are three main vision-limiting complications of  BRVO: macular edema, macular 
nonperfusion, and vitreous hemorrhage from neovascularization34,35,36,37. 
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In the acute phase (i.e., the first 3 to 6 months) after a branch vein occlusion, there is often 
extensive intra- retinal hemorrhage that may involve the macula and the foveal center. Under 
these circumstances, it is impossible to evaluate the vascular perfusion status by fluorescein 
angiography because the hemorrhage itself blocks the view of the retinal vessels.                                             
 
       Additionally, hemorrhage in the foveal center may reduce visual acuity, visual acuity 
that is reduced by hemorrhage may recover completely if there is no other cause for the visual 
loss, such as macular edema or macular non perfusion. Under these circumstances, the patient 
should be followed every 2 to 3 months until there is sufficient clearing of hemorrhage to 
allow evaluation by fluorescein angiography.  
 
      After the acute phase of the BRVO has passed and intraretinal hemorrhage has  mostly  
reabsorbed, which usually takes 3 to 6 months, fluorescein angiography should be obtained to 
delineate the retinal vascular characteristics that may have prognostic significance—macular 
edema, macular non perfusion, and large segments of capillary non perfusion that may 
portend eventual neovascularization. When fluorescein angiography demonstrates macular 
edema with cystoid involvement of the fovea, but no capillary nonperfusion, it is presumed 
that the macular edema is the cause of  loss of vision. Under these circumstances, about one 
third of patients will spontaneously regain some vision. 
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 When macular edema is present ophthalmoscopically within the first 6 months after a 
BRVO and there is little or no leakage on fluorescein angiography, macular ischemia may be 
the cause of  the macular edema.In such circumstances, the edema almost always 
spontaneously resorbs in the first year after the occlusion, often with return of vision38. 
   
   Retinal neovascularization may develop if the BRVO produces an area of capillary 
nonperfusion that is more than five disc diameters, as visualized with fluorescein 
angiography. In case of large branch vein occlusion (involving a quadrant or more), about 
50% are associated with a large area of capillary nonperfusion; of this 50%, about 40% will 
develop neovascularization. Retinal or disc neovascularization, or both, may develop at any 
time within the first 3 years after an occlusion but is most likely to appear within the first 6 to 
12 months  after the occlusion. Of patients  who develop neovascularization, approximately 
60% experience episodes of vitreous hemorrhage if the condition is left untreated. 
 
Investigations 
 
• Fluorescein Angiography 
          A fluorescein angiogram may be obtained as soon as the hemorrhages have cleared if 
the patient's vision is still diminished. This office-based test is usually done 3 or more months 
after the event.  Angiography is used to determine the cause of central visual loss (edema 
involving the central retina or macula vs. severe retinal capillary damage involving the 
macula--“macular ischemia”)10. 
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    If angiography suggests that visual loss is secondary to macular edema with good blood 
flow through the macular capillaries, laser photocoagulation in a “grid”  
pattern may be of  benefit. However, if angiography demonstrates the presence of  
extensive macular ischemia, laser photocoagulation may not be very effective and  
may therefore be withheld.  
 
•   Optical coherence tomography 
            Has ability to measure retinal thickness in a quantitative fashion, optical  
coherence tomography (OCT) is a useful adjunct in the evaluation of patients with  
macular edema secondary to BRVO. It is a safe, high-resolution, non-invasive, reliable and 
reproducible  method for detecting macular edema39. OCT delineates macular changes at a 
stage when fundus biomicroscopy and fluorescein angiography are not very informative. The 
anatomical cause for the increase in macular thickness and macular edema is also well 
delineated. Non-ischemic maculae show an early and more rapid decline in macular thickness 
compared with ischemic occlusions. An increase in macular thickness at 3 months on OCT in 
BRVO patients could be an indication of a possible ischemic course40. 
 
Treatment 
 
Treatment of BRVO can be considered under following head, namely, medical treatment, 
laser therapy, intravitreal triamcinolone and intravitreal anti-VEGF therapy. 
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Medical treatment 
 
Anticoagulant therapy has not been shown to be beneficial in either the prevention or the 
management of BRVO41. Since the systemic administration of anticoagulants can be asso-
ciated with systemic complications, and since anticoagulants could, in theory, increase the 
severity of intraretinal hemorrhage occurring in the acute phase, such therapy is not 
recommended42. 
 
Laser therapy 
 
The Collaborative Branch Vein Occlusion Study10 , a multi-center randomized clinical trial 
supported by the National Eye Institute(USA), reported that argon laser photocoagulation 
may reduce visual loss from macular edema for those eyes that meet study eligibility criteria 
and are treated according to that protocol. Important eligibility criteria included fluorescein - 
proven perfused macular edema involving the foveal center, absorption of intraretinal 
hemorrhage from the foveal center, recent branch retinal vein occlusion (usually of  3 to 18 
month  duration), absence of  diabetic retinopathy, and vision reduced to 20/40 or worse after 
best refraction. 
 
In the Collaborative Branch Vein Occlusion Study, argon laser photocoagulation was 
applied in a grid pattern throughout the area demonstrated by fluorescein angiography to be 
leaking. Coagulation  extended no closer to the fovea than the edge of the capillary-free zone 
and no farther into the periphery than the major vascular arcade. Recommended treatment 
parameters included a duration of 0.1 second, a 100 micron diameter spot size, and a power  
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setting sufficient to produce a "medium" white burn. Fluorescein angiography was repeated 
2 to 4 months after the treatment, and additional photocoagulation was applied to residual 
areas of leakage if reduced visual acuity persisted. When improvement was defined as 
reading two or more Snellen lines (beyond baselines) at two consecutive visits, the treated 
eyes  showed visual improvement  more often than the untreated eyes.  After 3 years of 
follow-up, 63% of treated eyes  gained two or more line of vision, compared to 36% of un-
treated eyes. The average gain in visual acuity for treated eyes was one more Snellen line 
than in untreated eyes10.  
 
In the application of grid pattern laser photocoagulation, it is crucial to obtain good 
definition of landmarks so that the center of the fovea can be identified and avoided. Since 
landmarks frequently may be obscured in the macula after BRVO, such cases can be 
managed more effectively and safely by treating well peripheral to the capillary-free zone in 
the first sitting. When the patient returns in 2 month for follow-up evaluation, a fluorescein 
angiogram may identify more clearly the amount of further treatment that needs to be applied 
closer to the edge of the capillary-free zone, because the pigmentation of the previous 
treatment is then visible. Consequently, treatment in this next sitting may be brought closer to 
the edge of the capillary-free  zone, if that is deemed necessary because of continued edema 
with foveal involvement and continued visual loss. The placement of grid laser treatment in 
this repetitively-staged fashion may be safer and appears to be just as effective as a single 
treatment. It has never been established that macular edema must be treated quickly or that 
long-standing edema produces irreversible macular damage in the first 2 to 3 years. 
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In the Collaborative Branch Vein Occlusion Study, Argon blue-green wavelength was 
employed for the grid treatment. This is the only wavelength that has been proved effective; it 
is not known whether argon-green or krypton-red photocoagulation would be as effective. In 
other diseases, when laser treatment is applied inside the capillary-free zone, it is recognized 
that krypton red and argon green laser photocoagulation are absorbed less than blue-green by 
the xanthophyll pigment of the inner retina that is present close to the foveal center. 
However, because the grid treatment never comes closer to the fovea than the capillary-free 
zone, the Branch Vein Occlusion Study did not encounter any problems with the argon blue-
green laser in this region; consequently, this laser continues to be recommended. 
 
The Branch Vein Occlusion Study demonstrated that prophylactic scatter laser 
photocoagulation can lessen subsequent neovascularization and if neovascularization already 
exists, that peripheral scatter laser photocoagulation can lessen subsequent vitreous 
hemorrhage43. Only eyes with the type of branch vein occlusion that shows large areas 
(greater than five disc diameters) of retinal capillary nonperfusion are at risk for developing 
neovascularization. It is recommended that laser photocoagulation be applied only after  
neovascularization is documented. The Branch Vein Occlusion Study data strongly suggest 
that photocoagulation after  the development of neovascularization is as effective in pre-
venting vitreous hemorrhage as is photocoagulation before the development of 
neovascularization . When neovascularization is unequivocally confirmed by fluorescein 
angiography. peripheral scatter laser photocoagulation can reduce from about 60% to 30% 
the likelihood of vitreous hemorrhage. Scatter laser photocoagulation is applied to achieve 
"medium" white burns (200 to 500 microns in diameter) spaced one burn width apart and  
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covering the entire area of capillary nonperfusion, as defined by fluorescein angiography, 
but not closer than 2  disc diameters from the center of the fovea and extending peripherally 
at least to the equator. 
 
Familiarity with the laser treatment technique is required to individualize the treatment. 
Important variables, such as residual intraretinal hemorrhage, thickness of the retina from 
edema , location of collaterals, and presence of retinal traction influence the exact mode of 
therapy within the above general treatment guidelines for the management of macular edema 
and neovascularization. There are numerous complications of laser photocoagulation; 
however, it is generally recognized that with proper attention to detail, complications are 
infrequent. Side effects of treatment, including production of scotoma, merit careful 
consideration and discussion with the patient before initiation of treatment. It is particularly 
important to recognize that laser photocoagulation should never be placed over extensive 
intraretinal hemorrhage in the acute phase of branch vein occlusion because the laser energy 
will be absorbed by the intraretinal hemorrhage rather than at the level of the pigment 
epithelium, probably damaging the nerve fiber layer and possibly producing preretinal 
fibrosis. 
 
Though BVO Study has been a bench mark study and laser therapy since then been the gold 
standard treatment, various other studies have also substantiated the beneficial role of 
laser44,45,46. Arnarsson A et al hypothesised that the disappearance of macular edema in 
BRVO can be explained by the effect the laser photocoagulation has on retinal oxygenation. 
Increased oxygenation causes vessel constriction and shortening and lower intravascular  
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pressure, which reduces edema formation according to Starling's law. Lang GE et al 
investigated the relationship of morphological and fluorescein angiographic findings with the 
results of laser treatment. They concluded that laser treatment in BRVO was beneficial and 
resulted in significant visual improvement. 
 
Intravitreal triamcinolone 
 
Scott IU et al14 compared compare the efficacy and safety of 1-mg and 4-mg doses of 
preservative-free intravitreal triamcinolone with standard care (grid photocoagulation in eyes 
without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears 
in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular 
edema secondary to branch retinal vein occlusion (SCORE TRIAL). They concluded that 
there was no difference identified in visual acuity at 12 months for the standard care group 
compared with the triamcinolone groups; however, rates of adverse events (particularly 
elevated intraocular pressure and cataract) were highest in the 4-mg group. Application to 
Clinical Practice Grid photocoagulation as applied in the SCORE Study remains the standard 
care for patients with vision loss associated with macular edema secondary to BRVO who 
have characteristics similar to participants in the SCORE-BRVO trial. Grid photocoagulation 
should remain the benchmark against which other treatments are compared in clinical trials 
for eyes with vision loss associated with macular edema secondary to BRVO. 
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Various previous studies47,48,49 have also showed beneficial effects of intravitreal 
triamcinolone therapy but have not been popular due to  relatively higher incidence of 
complications like glaucoma and cataract and also the need for repetitive injections. 
McAllister IL et al found intravitreal triamcinolone down regulates VEGF, which may 
prevent a decrease in occludin and also inhibits an increase in glial fibrillary acidic 
protein (GFAP) expression in Muller cells. These events  contributed to a reduction in the 
blood retinal barrier breakdown that occurs in BRVO and promote resolution of the 
associated retinal edema. Gunnlaugsdóttir E et al also found that intravitreal triamcinolone 
improves visual acuity in about 40% of patients with macular oedema, about 10% lose vision 
and about 50% remain unchanged. OCT revealed improved anatomic results with significant 
reduction of foveal thickness and macular oedema. Similarly Chen SD et al found that 
intravitral triamcinolone was effective in reducing ischemic macular edema associated with 
BRVO and foveal capillary nonperfusion. . Raised IOP and development of posterior 
subcapsular cataract are disadvantages of this treatment. 
 
 
Intravitreal anti-VEGF  
 
Recently, there has been interest in the use of  VEGF  inhibition in the treatment of BRVO 
because of the observation of increased VEGF in the vitreous and aqueous of patients with 
these conditions8,9.Mainly intravitreal bevacizumab (Avastin)has been used with recent 
introduction of intravitreal ranibizumab (Lucentis).Both will be studied in detail below. 
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Bevacizumab 
Bevacizumab is an immunoglobulin G (IgG) composed of two identical light chains, 
consisting of 214 amino acid residues and two 453 residue heavy chains containing an N-
linked oligosaccharide and has a molecular weight of approximately 149Kda50,51. 
 
Description52 - It is a clear to slightly opalescent, colourless to pale brown sterile solution 
for intravenous (IV) infusion, available in 100 mg and 400 mg single dose vials containing 4 
mL and 16 mL, respectively of bevacizumab (25 mg/mL). Bevacizumab  also contains a 
trehalose dihydrate, monobasic monohydrate sodium phosphate, dibasic sodium phosphate, 
polysorbate 20 and water for injections. 
  
Mechanism of action52 -  Bevacizumab is a recombinant humanised monoclonal antibody 
that selectively binds to and neutralises the biologic activity of human  VEGF . Bevacizumab 
contains human framework regions with antigen binding regions of a humanised murine 
antibody that binds to VEGF. Bevacizumab is produced by recombinant DNA technology in 
a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing 
the antibiotic gentamicin and is purified by a process that includes specific viral inactivation 
and removal steps. Gentamicin is detectable in the final product at <= 0.35 ppm. 
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Bevacizumab inhibits the binding of VEGF to its receptors, Flt-1 and KDR, on the surface 
of endothelial cells. Neutralising the biologic activity of VEGF reduces the vascularisation of 
tumours, thereby inhibiting tumour growth. Administration of bevacizumab or its parental 
murine antibody to xenotransplant models of cancer in nude mice resulted in extensive 
antitumour activity in human cancers, including colon, breast, pancreas and prostate. 
Metastatic disease progression was inhibited and microvascular permeability was reduced. 
 
Pharmacokinetics53 - Whereas vitreous concentrations of bevacizumab declined in a 
monoexponential fashion with a half-life of 4.32 days, concentrations of >10μg/ml 
bevacizumab were maintained in the vitreous humor for 30 days. Bevacizumab 
concentrations in the aqueous humor of the injected eye reached a peak concentration of 37.7 
μg/ml 3 days after drug administration. A maximum serum concentration of 3.3 μg/ml was 
achieved 8 days after intravitreal injection and the concentration fell below 1 μg/ml 29 days 
after injection. Elimination of bevacizumab from the aqueous humor and serum paralleled 
that found in the vitreous humor, with half-life values of 4.88 days and 6.86 days, 
respectively. Very low concentrations of bevacizumab were detected in the fellow uninjected 
eye. Concentrations of bevacizumab in the vitreous of the fellow eye varied incrementally, 
from 0.35 ng/ml at 1 day to 11.17 ng/ml at 4 weeks. Concentrations of bevacizumab in the 
aqueous humor of the fellow eye reached their peak at 1 week, at 29.4 ng/ml, and declined to 
4.56 ng/ml at 4 weeks. 
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Pharmacokinetics in Special Populations - The population pharmacokinetics of bevacizumab 
were analysed to evaluate the effects of demographic characteristics. The results showed no 
significant difference in" the pharmacokinetics of bevacizumab in relation to age. 
 
Children and Adolescents: No formal studies have been conducted to examine the 
pharmacokinetics of bevacizumab in children and adolescent patients. 
 
Renal impairment: No formal studies have been conducted to examine the 
pharmacokinetics of bevacizumab in subjects with renal impairment 
 
Hepatic impairment: No formal studies have been conducted to examine the 
pharmacokinetics of bevacizumab in subjects with hepatic impairment. 
 
 
Complication54,55,56 -  General complications – Cataract, Glaucoma,  Vitreous 
Hemorrhage, Retinal detachment,  Endophthalmitis. 
 Specific Complications - Retinal pigment epithelial rip, Submacular haemorrhage, 
Progression of tractional retinal detachment, Visual hallucinations. 
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Bevacizumab in various diseases 
BRVO - Prager F et al11 evaluated functional and anatomical changes after intravitreal 
bevacizumab (Avastin) in eyes with persistent macular oedema secondary to branch retinal 
vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Twenty-nine consecutive 
eyes with macular oedema secondary to BRVO (21 eyes) or CRVO (eight eyes) were 
included in a prospective clinical trial. Eyes were treated with three initial intravitreal 
bevacizumab injections of 1 mg at a monthly interval. Retreatment was based on central 
retinal thickness (CRT) based on optical coherence tomography. If continuous injections 
were indicated up to month 6, the dose was increased to 2.5 mg. After 12 months of follow-
up, mean visual acuity increased from 50 letters (20/100) at baseline to 66 letters (20/50(+1); 
+16 letters; p<0.001) at month 12 and CRT decreased from 558 mum at baseline to 309 mum 
at month 12 (-249 mum; p<0.001). Patients received a mean of eight out of 13 possible 
injections. No drug-related systemic or ocular side effects following intravitreal bevacizumab 
treatment were observed. Fluorescein angiography revealed no progression of avascular 
areas.They concluded that Intravitreal therapy using bevacizumab appears to be a safe and 
effective treatment in patients with macular oedema secondary to retinal vein occlusion. 
However, the main limitations of this treatment modality are its short-term effectiveness and 
high recurrence rate. 
Jaissle GB et al12 investigated the long-term effectiveness of intravitreal bevacizumab 
treatment in eyes with perfused macular edema due to branch retinal vein occlusion (BRVO). 
23 consecutive, previously untreated eyes with perfused macular edema were treated with 
intravitreal bevacizumab (1.25 mg) injections and followed for 1 year. 
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 The main outcome measures were visual acuity (VA) and central retinal thickness (CRT). In 
addition, VA data were adapted to the non-logarithmic VA charts used in the previously 
published grid laser photocoagulation BRVO Study. The median VA gained 3.0 lines from 
baseline at 48 weeks. This was accompanied by a significant decrease of 39% of the median 
CRT. The mean number of re-injections was 1.6 during the first 6 months of follow-up and 
only 0.8 during the subsequent 6 months. In 65% of the cases, adapted VA data showed a 
gain of 1 or more lines and no eye lost more than 1 line. They stated  that  repetitive 
intravitreal bevacizumab injections result in a significant long-term improvement of VA and 
CRT. The number of re-injections necessary to maintain this effect declined over time. 
However, the treatment seems to be only slightly better than grid laser photocoagulation. 
Kondo M et al13 evaluated the 12-month follow-up results of intravitreal bevacizumab 
therapy for macular edema secondary to branch retinal vein occlusion and to identify the 
pretreatment factors that were associated with an improvement of the final visual outcome. 
Fifty eyes of 50 patients with macular edema secondary to branch retinal vein occlusion 
received an injection of 1.25 mg/0.05 mL bevacizumab. Additional injections were done 
when recurrence of macular edema occurred or the treatment was not effective. The best-
corrected visual acuity and foveal thickness were measured. Stepwise multiple regression 
analyses were also performed. Visual acuity improved significantly from 0.53 to 0.26, and the 
mean foveal thickness decreased significantly from 523 to 305 μm during the 12-month 
follow-up period. The mean number of injections was 2.0 (range, 1-4). 
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 Stepwise multiple regression analyses showed that younger patients had both better visual 
acuity at 12 months and greater improvement of visual acuity during 12 months. In addition, 
better pretreatment visual acuity was associated with better visual acuity at 12 months but 
with less improvement of the visual acuity.They concluded that intravitreal bevacizumab 
therapy can be a long-term effective treatment for macular edema secondary to branch retinal 
vein occlusion. 
 
CRVO - Costa RA  et al 57 evaluated the safety, visual acuity changes, and morphologic 
effects associated with intravitreal bevacizumab injections for the management of macular 
edema due to  central retinal vein occlusion (CRVO) and Hemi central retinal vein 
occlusion(H-CRVO). In this prospective, open-label study, 7 consecutive patients (7 eyes) 
with macular edema associated with  central or hemicentral RVO were treated with 
intravitreal-injections of 2.0 mg (0.08 mL) of bevacizumab at 12-week interval. Concluded 
that Intravitreal bevacizumab injections of 2.0 mg at 12-week intervals were well tolerated 
and were associated with short-term BCVA stabilization or  improvement and favourable 
macular changes in all patients with ischemic CRVO and associated macular edema. 
 
Diabetic retinopathy - Haritoglou C  et al58 evaluated the efficacy of bevacizumab for the 
treatment of diabetic macular edema in 51 consecutive patients with diffuse diabetic macular 
edema. Concluded that diffuse diabetic macular edema not responding to previous treatments 
such as photocoagulation, intravitreal injection of triamcinolone, or vitrectomy, improvement 
of visual acuity and decrease of retinal thickness could be observed after intravitreal injection  
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of bevacizumab. Although follow-up period was too short to provide specific treatment 
recommendations, the short-term results encourage further prospective studies with different 
treatment groups and longer follow-up. 
 
Ranibizumab 
Ranibizumab ( Lucentis) is a 48 Kda, monoclonal antibody fragment (Fab) derived from the 
same parent murine antibody as bevacizumab (Avastin). It is much smaller than the parent 
molecule and has been affinity matured to provide stronger binding to VEGF-A. It is able to 
cross the internal limiting membrane and gain access in the sub-retinal space59. 
 
Description60 - Ranibizumab is a sterile, colorless to pale yellow solution in a single-use 
glass vial. Ranibizumab is supplied as a preservative-free, sterile solution in a single-use 
glass vial designed to deliver 0.05 mL of 10 mg/mL It is a aqueous solution with 10 mM 
histidine HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 20, pH 5.5. 
 
Mechanism of action59 - Ranibizumab is a recombinant humanized IgG1 kappa isotype 
monoclonal antibody fragment designed for intraocular use. Ranibizumab has a molecular 
weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a 
nutrient medium containing the antibiotic tetracycline.  
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Tetracycline is not detectable in the final product. Ranibizumab binds to and inhibits the 
biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab 
binds to the receptor binding site of active forms of VEGF-A, including the biologically 
active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause 
neovascularization and leakage in models of ocular angiogenesis. The binding of ranibizumab 
to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) 
on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, 
and new blood vessel formation. 
Pharmacokinetics60 - Although vitreous concentrations of ranibizumab declined in a 
monoexponential fashion with a half-life of 2.88 days, concentrations of >0.1 μg/ml 
ranibizumab were maintained in the vitreous humor for 29 days. Ranibizumab concentrations 
in the aqueous humor of the injected eye reached a peak concentration of 17.9 μg/ml, 3 days 
after drug administration. Elimination of ranibizumab from the aqueous humor paralleled that 
found in the vitreous humor, with a half-life value of 2.84 days. No ranibizumab was detected 
in the serum or the fellow eye.  
Pharmacokinetics in Special population - The population pharmacokinetics of ranibizumab 
were analysed to evaluate the effects of demographic characteristics. The results showed no 
significant difference in  the pharmacokinetics of ranibizumab in relation to age. 
Pregnancy  - Animal reproduction studies have not been conducted with ranibizumab.It is 
also not known whether ranibizumab can cause fetal harm when administered to a pregnant 
woman or can affect reproduction capacity. 
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Ranibizumab should be given to pregnant woman only if clearly indicated. 
 
Nursing mothers – it is not known whether ranibizumab is excreted in human 
milkl.Because many drugs are excreted in human milk , and because of the potential for 
absorption and harm to the infant growth and development exists, caution should be advised 
when ranibizumab is administered to nursing woman. 
 
Peadriatic use – safety and efficacy in paediatric patients has not been established. 
 
Geriatric  use - In the controlled clinical studies, approximately 94% (822/879) of the 
patients randomized to treatment with Ranibizumab were >65 years of age and approximately 
68% (601/879) were >75 years of age. No notable difference in treatment effect was seen 
with increasing age in any of the studies. Age did not have a significant effect on systemic 
exposure in a population pharmacokinetic analysis after correcting for creatinine clearance. 
 
Patients with Renal Impairment - No formal studies have been conducted to examine the 
pharmacokinetics of ranibizumab in patients with renal impairment. Sixty-eight percent of 
patients (136 of 200) in the population pharmacokinetic analysis had renal impairment 
(46.5% mild, 20% moderate, and 1.5% severe). Reduction in ranibizumab clearance is 
minimal in patients with renal impairment and is considered clinically insignificant. Dose 
adjustment is not expected to be needed for patients with renal impairment. 
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Patients with Hepatic Dysfunction - No formal studies have been conducted to examine the 
pharmacokinetics of ranibizumab in patients with hepatic impairment.Dose adjustment is not 
expected to be needed for patients with hepatic dysfunction. 
 
Complications59 - General complications – Cataract, Glaucoma,  Vitreous Hemorrhage, 
Retinal detachment,  Endophthalmitis. 
Specific complications – thromboembolic episodes, conjunctival hemorrhage, eye pain, 
vitreous floaters, increased intraocular pressure, and intraocular inflammation. 
 
 
Ranibizumab in various diseases 
 
BRVO - Campochiaro PA et al16 evaluated efficacy and safety of intraocular injections of 0.3 
mg or 0.5 mg ranibizumab in patients with macular edema following branch retinal vein 
occlusion (BRAVO TRIAL).  A total of 397 patients with macular edema following BRVO 
were enrolled in the study. They found that Mean (95% confidence interval [CI]) change 
from baseline BCVA letter score at month 6 was 16.6 (14.7-18.5) and 18.3 (16.0-20.6) in the 
0.3 mg and 0.5 mg ranibizumab groups and 7.3 (5.1-9.5) in the sham group (P<0.0001 for 
each ranibizumab group vs sham). The percentage of patients who gained > or =15 letters in 
BCVA at month 6 was 55.2% (0.3 mg) and 61.1% (0.5 mg) in the ranibizumab groups and 
28.8% in the sham group (P<0.0001 for each ranibizumab group vs sham).  
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At month 6, significantly more ranibizumab-treated patients (0.3 mg, 67.9%; 0.5 mg, 64.9%) 
had BCVA of > or =20/40 compared with sham patients (41.7%; P<0.0001 for each 
ranibizumab group vs sham); and CFT had decreased by a mean of 337 microm (0.3 mg) and 
345 microm (0.5 mg) in the ranibizumab groups and 158 microm in the sham group 
(P<0.0001 for each ranibizumab group vs sham). The median percent reduction in excess 
foveal thickness at month 6 was 97.0% and 97.6% in 0.3 mg and 0.5 mg groups and 27.9% in 
the sham group. More patients in the sham group (54.5%) received rescue grid laser 
compared with the 0.3 mg (18.7%) and 0.5 mg (19.8%) ranibizumab groups. The safety 
profile was consistent with previous phase III ranibizumab trials, and no new safety events 
were identified in patients with BRVO.They concluded that Intraocular injections of 0.3 mg 
or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following 
BRVO with low rates of ocular and nonocular safety events. 
 
Rouvas A et al17 evaluated the effect of individualized repeated intravitreal injections of 
ranibizumab on visual acuity and central foveal thickness (CFT) for branch retinal vein 
occlusion-induced macular edema. Twenty-eight eyes of 28 consecutive patients diagnosed 
with branch retinal vein occlusion-related macular edema treated with repeated intravitreal 
injections of ranibizumab (when CFT was >225 microm) were evaluated. Optical coherence 
tomography and fluorescein angiography were performed monthly. The mean best-corrected 
distance visual acuity improved from 62.67 Early Treatment of Diabetic Retinopathy Study 
letters (logarithm of the minimum angle of resolution = 0.74 +/- 0.28 [mean +/- standard 
deviation]) at baseline to 76.8 Early Treatment of Diabetic Retinopathy Study letters 
(logarithm of the minimum angle of resolution = 0.49 +/- 0.3; statistically significant, P <  
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0.001) at the end of the follow-up (9 months). The mean letter gain (including the patients 
with stable and worse visual acuities) was 14.3 letters (2.9 lines). During the same period, 22 
of the 28 eyes (78.6%) showed improved visual acuity, 4 (14.2%) had stable visual acuity, 
and 2 (7.14%) had worse visual acuity compared with baseline. The mean CFT improved 
from 349 +/- 112 microm at baseline to 229 +/- 44 microm (significant, P < 0.001) at the end 
of follow-up. A mean of six injections was performed during the follow-up period. Our 
subgroup analysis indicated that patients with worse visual acuity at presentation (<or=50 
letters in our series) showed greater visual benefit from treatment. "Rebound" macular edema 
was observed in 5 patients (17.85%) at the 3-month follow-up visit and in none at the 6- and 
9-month follow-ups. In 18 of the 28 patients (53.6%), the CFT was <225 microm at the last 
follow-up visit, and therefore, further treatment was not instituted. No ocular or systemic side 
effects were noted. They also concluded similar findings that Individualized repeated 
intravitreal injections of ranibizumab showed promising short-term results in visual acuity 
improvement and decrease in CFT in patients with macular edema associated with branch 
retinal vein occlusion.  
 
CRVO - Brown DM et al61 also evaluated efficacy and safety of intraocular injections of 0.3 
mg or 0.5 mg ranibizumab in patients with macular edema after central retinal vein occlusion 
(CRUISE TRIAL).A total of 392 patients with macular edema after CRVO were enrolled in 
the study.They found Mean (95% confidence interval [CI]) change from baseline BCVA 
letter score at month 6 was 12.7 (9.9-15.4) and 14.9 (12.6-17.2) in the 0.3 mg and 0.5 mg  
29 
 
 
 
ranibizumab groups, respectively, and 0.8 (-2.0 to 3.6) in the sham group (P<0.0001 for each 
ranibizumab group vs. sham). The percentage of patients who gained > or =15 letters in 
BCVA at month 6 was 46.2% (0.3 mg) and 47.7% (0.5 mg) in the ranibizumab groups and 
16.9% in the sham group (P<0.0001 for each ranibizumab group vs. sham). At month 6, 
significantly more ranibizumab-treated patients (0.3 mg = 43.9%; 0.5 mg = 46.9%) had 
BCVA of > or = 20/40 compared with sham patients (20.8%; P<0.0001 for each ranibizumab 
group vs. sham), and CFT had decreased by a mean of 434 microm (0.3 mg) and 452 microm 
(0.5 mg) in the ranibizumab groups and 168 microm in the sham group (P<0.0001 for each 
ranibizumab group vs. sham). The median percent reduction in excess foveal thickness at 
month 6 was 94.0% and 97.3% in the 0.3 mg and 0.5 mg groups, respectively, and 23.9% in 
the sham group. The safety profile was consistent with previous phase III ranibizumab trials, 
and no new safety events were identified in patients with CRVO.They finally concluded 
 Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-
month visual acuity and macular edema following CRVO, with low rates of ocular and 
nonocular safety events. 
Diabetic retinopathy - Nguyen QD et al62 compared ranibizumab with focal/grid laser or a 
combination of both in diabetic macular edema (DME). They concluded that During a span 
of 6 months, ranibizumab injections by the current protocol had a significantly better visual 
outcome than focal/grid laser treatment in patients with DME. 
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MATERIALS AND METHODS 
 
Study Design 
y It is an investigative , open-label, randomized prospective interventional study done to 
collect the long-term efficacy and safety data in Indian patients with visual 
impairment due to macular edema secondary to branch retinal vein occlusion.  
 
 
Inclusion Criteria 
• Patients with macular edema due to BRVO  (confirmed by fundus photography, 
fluorescein angiography, OCT) 
• Male and female aged from 35 years and above 
• Baseline best-corrected visual acuity (BCVA) in the study eye Study Eye < 6/12 using 
Snellen chart 
• Central macular thickness on OCT >250 microns  
• Patients willing to provide signed, written informed consent 
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Exclusion Criteria 
• Additional eye disease that could compromise VA 
• Ocular inflammation 
• Intraocular surgery ≤1 month before presentation 
• Uncontrolled glaucoma 
• Prior treatments with laser photocoagulation or other intervention for macular edema due 
to BRVO 
• Pregnancy 
 
Treatment  Groups 
y Ranibizumab group - Ranibizumab(single dose) + Laser.     
y Bevacizumab group - Bevacizumab ( single dose) + Laser. 
y Laser group – Laser only. 
 
Study Duration 
6 months. 
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Methodology 
All eligible patients were randomized to one of the three treatment group. Patients 
were followed until 6 months. Primary end point in this study was to  assess the  
efficacy of  ranibizumab 0.5 mg , by evaluating  mean change from baseline in best-
corrected visual acuity (BCVA).  Secondary endpoints in this study included the 
evaluation of tolerability and safety of ranibizumab 0.5 mg , and the Best corrected 
Visual acuity on snellens chart, intraretinal thickness changes in Optical Coherence 
Tomography (OCT) and Intraocular safety of intravitreal injection of Ranibizumab in 
comparison to intravitreal Bevacizumab and laser. 
 
Ethics 
The design and methodology of the study were reviewed by the Institutional Review  
Board prior to the start of the investigation. In addition, written informed consent was 
obtained from each individual patient prior to enrolment in the study. 
 
Number Of Patients  
 30 eyes of 30 patients with  macular edema  due  to branch retinal vein occlusion 
were recruited and then randomized to one of the three treatment arms. 
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Population 
Male or female outpatients, above 18 years of age, with macular edema secondary to 
branch retinal vein occlusion , as determined by the ophthalmologists . 
 
Drug Used 
Lucentis (Ranibizumab)  0.5 mg (0.05 ml volume) intravitreal injection. 
Avastin (Bevacizumab) 1.25 mg (0.05 ml volume) intravitreal injection. 
 
Procedure 
y In Ranibizumab group - 0.05 ml of  ranibizumab containing 0.5 mg of drug was 
injected intravitreally. 
y In Bevacizumab group – 0.05 ml of  bevacizumab containing 1.25mg of drug was 
injected intravitreally. 
y Both Ranibizumab group and Bevacizumab group  underwent one sitting of laser 
within 7 to 10 days of anti VEGF injection.   
y In Laser group – 532 nm green laser photcoagulation  was applied in a grid pattern. 
Parameters include a duration of 0.1 second &100 micron diameter spot size. 
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Visit Schedule 
During this visit 1 (baseline, Week 0), the patient's eligibility for the study was assessed 
according to the inclusion & exclusion criteria. At Visit 1, the following information was 
collected to allow adequate characterization of the disease and the patient’s medical history; 
Workup Parameters (Baseline and follow up) 
y Best corrected visual acuity  
y Slit lamp bimicroscopy  
y Direct and indirect ophthalmoscopy  
y IOP 
y Clinical fundus photography  
y Fundus fluorescein angiography  
y Optical coherence tomography  
Follow up of patients was done 1st, 3rd and 6 months. 
Efficacy Parameters 
The evidence of clinical efficacy was evaluated on the basis of mean change in BCVA and 
CFT at 6 months. Visual acuity (VA) measurement with snellen charts, intraretinal structure 
changes in OCT .This evaluation was done at various time points throughout the study as 
explained. 
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Definitions 
Significant visual gain (Snellen’s chart) =  gain of  ≥ 3 lines on Snellen’s chart at 6 months 
from the baseline. 
Significant visual gain (percentage) = gain of  ≥ 200% in terms of mean percentage change of 
BCVA(Decimals) at 6 months from baseline. 
Significant decrease in macular thickness (microns) = reduction of  ≥ 200 microns on OCT at 
6 months from baseline. 
Significant decrease in macular thickness (percentage) = reduction of ≥ 200% in terms of 
mean percentage reduction of macular thickness on OCT at 6 months from beseline. 
Retreatment requirement – loss of more than 1 line or increase in CFT more than 100 microns 
from previous visit.. 
 
 
Safety and Tolerability 
Safety and Tolerability assessments (both ocular and systemic) was monitored and all adverse 
events and serious adverse events were recorded. 
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Statistical Analysis 
Quantitative variables under primary & secondary endpoints, BCVA measurement 
(Decimals) , changes in intraretinal thickness on OCT (Microns) etc. (at baseline and follow-
up visit’s)  was described in terms of their descriptive statistics (extreme values, Minimum 
and Maximum), Mean, Standard Deviation. 
For the Quantitative variables (as described above) , Paired ‘t’ test  in case the variables did 
not follow normal distribution, was performed to assess the statistical significance of the 
differences between  baseline and end of study under each group separately. 
A percentage (%)  change in secondary end point was  computed   between the base line and 
end of study and  will be tested by  Student ‘t’ test. 
For intergroup comparisons regarding above mentioned quantitative variables in case the 
variables did not follow normal distribution between the three treatment groups, one way 
analysis of variance (ANOVA) was done. 
Differences between the gender distribution in the different study groups, differences 
between proportions of patients exhibiting , visual gain of ≥ 3 lines and differences between 
proportion of patients showing ≥ 200% improvement in BCVA at 6 months, and ≥ 200% 
reduction in CFT at 6 months, were assessed for significance by the Chi-square test with 
Yates correction. 
In all the analysis, a probability (p) value of ≤ 0.05 was considered statistically significant.  
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 RESULTS 
 
This investigative, open-label, prospective randomized interventional study was performed at 
the retina clinic of a tertiary eye care facility in southern India over a period of 12 months ( 
1st June 2009 to 31st May 2010). Thirty patients (30 eyes), comprising 12 males and 18 
females (age range 38 to 74 years), who presented with macular edema due to BRVO during 
the study period, who satisfied the inclusion criteria and who provided consent for 
participation, were included in the study.  
 
Upon presentation (baseline) and after ensuring that all investigational requirements were 
satisfied, each patient was randomly assigned (by random numbers) to one of three 
interventional groups : ranibizumab, bevacizumab or  laser. Thus, each interventional group 
consisted of 10 patients (10 eyes).Patient demographics and baseline ocular characteristics 
did not differ significantly across all the interventional groups (Tables 1, 2 and 3).  
 
Patients who were treated with ranibizumab ranged in age from 42 to 74 years, with a mean 
age of 58.8 + 9.47 years,  those treated with bevacizumab ranged in age from 38 to 68 years, 
with a mean age of 58.4 +   8.55 years, and those treated with laser ranged in age from 38 to 
69 years , with a mean age of 57.0 + (SD) 8.97 years  (Table 1, Fig. 1 ); these differences  
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were not statistically significant (one-way analysis of variance [ANOVA],  degree of freedom 
[d.f.] =2; Fisher F-value=0.110; P=0.896).  
 
Males comprised two (20%) of 10 patients who were treated with ranibizumab, six (60%) of 
10 patients who were treated with bevacizumab and  four (40%) of the 10 patients who were 
treated with laser (Table 2); these differences were not statistically significant (chi-square 
with Yates correction [d.f. = 5}= 3.33; P [2 tailed] =0.6487 ).  
 
In addition to macular edema,  29 (97%) of  the 30 study patients suffered from associated 
systemic diseases, namely hypertension and/or diabetes mellitus(Table 3). Thus, hypertension 
alone occurred in seven (70%), diabetes mellitus alone in one (10%) and hypertension and 
diabetes mellitus in two (20%) of 10 patients who were treated with ranibizumab; 
hypertension alone occurred in eight (80%) and hypertension and diabetes mellitus occurred 
in one (10%) of 10 patients who were treated with bevacizumab;  hypertension alone 
occurred in seven (70%) and hypertension and diabetes mellitus in three (30%) of the 10 
patients treated with laser  (Table 3). These differences were not statistically significant.  
 
One of the key outcomes assessed was the best corrected visual acuity (BCVA) in the three 
interventional groups at four different points of time: baseline (presentation), and one month, 
three months and six months  after the intervention (Table 5). At baseline, the mean BCVA  
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(in decimals) in the ranibizumab, bevacizumab and laser treatment groups was 0.177 +  
0.085, 0.1663  + 0.103  and 0.21 + 0.12 , respectively; these differences were not statistically 
significant (ANOVA [d.f.=2]; Fisher F-value= 0.48; P = 0.622). The same trend was 
observed at the subsequent points of time when patients were evaluated. At one month after 
intervention, the mean BCVA (in decimals) in the ranibizumab, bevacizumab and laser 
treatment groups was0.397 +  0.17, 0.365  + 0.23  and 0.38 + 0.28 , respectively; these 
differences were not statistically significant (ANOVA [d.f.=2]; Fisher F-value= 0.048; P = 
0.953). At three months following intervention, the mean BCVA (in decimals) in the 
ranibizumab, bevacizumab and laser  treatment groups was 0.423 +  0.13, 0.337  + 0.23  and 
0.399 + 0.28 , respectively; these differences were not statistically significant (one-way 
ANOVA [d.f.=2]; Fisher F-value= 0.399; P = 0.1). At six months following intervention, the 
mean BCVA (in decimals) in the ranibizumab, bevacizumab and laser treatment groups was 
0.44 +  0.12, 0.38  + 0.21  and 0.399 + 0.28 , respectively; these differences were not 
statistically significant (ANOVA [d.f.=2]; Fisher F-value= 0.206; P = 0.815)(Table 5). 
 
 Thus, no significant inter-group differences were noted in BCVA achieved. However, there 
was a significant intragroup difference when the ranibizumab group was considered in its 
entirety(Table 5). In these patients, the mean  BCVA (in decimals) at baseline and at one 
month, three months and six months after intervention was  0.177 ±  0.085, 0.397 ± 0.17, 
0.423± 0.13, and  0.44 ±  0.12 respectively; this difference was statistically significant (one-
way ANOVA [d.f.=3]; Fisher F-value = 8.943; P= 0.000). Similarly, significant differences  
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were observed  between the mean BCVA at  baseline (0.177 ±  0.085 decimals) and that at 
one month (0.397 ± 0.17 decimals)(student `t’test [d.f.=18] = 3.6603; P[2-tailed]= 0.0018), 
between the baseline BCVA value and that at three months (0.423± 0.13 decimals ) [student 
`t’test (d.f.=18) = 5.0084; P[2-tailed]= 0.0001) and between the baseline BCVA value and  
that at six months (0.44 ±  0.12 decimals) [student `t’test (d.f.=18) = 5.6556; P[2-tailed]= < 
0.0001)(Table 5). In this group, there were no significant differences between the mean 
BCVA values at one month versus three months, one month versus six months , and three 
months versus six months(Table 5).  
 
No significant intragroup difference in BCVA values was observed when the bevacizumab 
group was considered in its entirety(Table 5). In these patients, the mean  BCVA (in 
decimals) at baseline and at one month, three months and six months after intervention was  
0.1663 ±  0.103, 0.365 ± 0.23, 0.337 ± 0.23, and  0.38 ±  0.21 respectively; this difference 
was not statistically significant (one-way ANOVA [d.f.=3]; Fisher F-value = 2.433; 
P=0.081). However, significant differences were observed  between the mean BCVA at  
baseline (0.1663 ±  0.103 decimals) and that at one month (0.365 ± 0.23 decimals)(student 
`t’test [d.f.=18] = 2.4933; P[2-tailed]= 0.0266), between the baseline BCVA value and that at 
three months (0.337 ± 0.23 decimals) [student `t’test (d.f.=18) = 2.1420; P[2-tailed]= 0.0461) 
and between the baseline BCVA value and  that at six months (0.38 ±  0.21 decimals) 
[student `t’test (d.f.=18) = 2.8892; P[2-tailed]= 0.0098).  In this group (bevacizumab treated),  
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there were no significant differences between the mean BCVA values at one month versus 
three months, one month versus six months , and three months versus six months(Table 5).  
 
With reference to the BCVA values in when the laser group was considered in its entirety, no 
significant intragroup difference in BCVA values was observed(Table 5). In  the patients who 
received laser, the mean  BVCA (in decimals) at baseline and at one month, three months and 
six months after intervention was  0.21 + 0.12, 0.38 +  0.28, 0.399 + 0.280, and  0399 + 0.28, 
respectively; this difference was not statistically significant (one-way ANOVA [d.f.=3]; 
Fisher F-value = 1.350; P=0.274). There was also no significant difference between the mean 
BCVA at  baseline (0.21 + 0.12 decimals) and that at one month (0.38 +  0.28 
decimals)(student `t’test [d.f.=18] = 1.7647; P= 0.946), that at three months (0.399 + 0.280 
decimals) [student `t’test (d.f.=18) = 1.9619; P= 0.0654) and that at six months (0.399 + 
0.280 decimals) [student `t’test (d.f.=18) = 1.9619; P= 0.0654)(Table 5).  
 
Another key outcome assessed was the central foveal thickness (CFT) in the three 
interventional groups at four different points of time: baseline (presentation), and one month, 
three months and six months  after the intervention (Table  6). At baseline, the mean CFT (in 
microns) in the ranibizumab, bevacizumab and laser treatment groups was 623.2 ± 328.04,  
561.2 ±  187 and 511 +  135.52 respectively; these differences were not statistically 
significant (ANOVA [d.f.=2]; Fisher F-value= 0. 589;  P = 0.562).  
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The same trend was observed at the subsequent points of time when patients were 
evaluated(Table 6). At one month after intervention, the mean CFT (in microns) in the 
ranibizumab, bevacizumab and laser  treatment groups was 236.6  ±  126.37 , 254.3 ±  106.9 
and 274.1 +  83.41  respectively; these differences were not statistically significant (ANOVA 
[d.f.=2]; Fisher F-value= 0.307; P = 0.738). At three months following intervention, the mean 
CFT(in microns) in the  ranibizumab, bevacizumab and laser treatment groups was 216.0  ±  
69.12, 284.7 ±  130.4  and 207.2 +  39.52 , respectively; these differences were not 
statistically significant (one-way ANOVA [d.f.=2]; Fisher F-value= 2.314; P = 0.118). At six 
months following intervention, the mean CFT (in microns) in the ranibizumab, bevacizumab 
and laser treatment groups was 216.2  ±  63.85, 241.0 ±    88.9  and 204.1 +  38.34 , 
respectively; these differences were not statistically significant (ANOVA [d.f.=2]; Fisher F-
value= 0.789; P = 0.464)(Table 6). 
 
Thus, no significant inter-group differences were noted in the CFT. However,  significant 
intragroup differences were noted when each of the treatment groups was considered in its 
entirety(Table 6). In the ranibizumab group,  the mean  CFT (in microns) at baseline and at 
one month, three months and six months after intervention was  623.2 ± 328.04, 236.6  ±  
126.37, 216.0  ±  69.12 and 216.2  ±  63.85, respectively; this difference was statistically 
significant (one-way ANOVA [d.f.=3]; Fisher F-value = 12.126; P= 0.000). Similarly, in this 
ranibizumab treated group, significant differences were observed  between the mean CFT at  
baseline (623.2 ± 328.04 microns) and that at one month (236.6  ±  126.37 microns)(student  
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`t’test [d.f.=18] = 3.4777; P[2-tailed]= 0.0027), between the baseline CFT value and that at 
three months (216.0  ±  69.12 microns ) [student `t’test (d.f.=18) = 3.8410; P[2-tailed]= 
0.0012) and between the baseline CFT value and  that at six months (216.2  ±  63.85 microns) 
[student `t’test (d.f.=18) = 3.8512; P[2-tailed]=  0.0012)(Table 6). In this ranibizumab treated 
group, there were no significant differences between the mean CFT values at one month 
versus three months, one month versus six months , and three months versus six 
months(Table 6). 
A significant intragroup difference in mean  CFT values was observed when the bevacizumab 
group was considered in its entirety(Table 6). In these  patients,  the mean  CFT (in microns) 
at baseline and at one month, three months and six months after intervention was  561.2 ±  
187.0, 254.3 ±  106.9, 284.7 ±  130.4 and 241.0 ±    88.9, respectively; this difference was 
statistically significant (one-way ANOVA [d.f.=3]; Fisher F-value = 12.911; P=0.000). In 
this bevacizumab-treated group, significant differences were also observed  between the 
mean CFT at  baseline (561.2 ±  187.0 microns) and that at one month (254.3 ±  106.9 
microns)(student `t’test [d.f.=18] = 4.5056; P[2-tailed]= 0.0003), between the baseline CFT 
value and that at three months (284.7 ±  130.4  microns) [student `t’test (d.f.=18) = 3.8354; 
P[2-tailed]= 0.0012) and between the baseline CFT value and  that at six months (241.0 ±    
88.9  microns) [student `t’test (d.f.=18) = 4.8903; P[2-tailed]= 0.0001).  In this group 
(bevacizumab-treated), there were no significant differences between the mean CFT values at 
one month versus three months, one month versus six months , and three months versus six 
months(Table 6).  
 
44 
 
 
With reference to mean CFT values in the laser group, a significant intragroup difference was 
observed(Table 6). The mean  CFT (in microns) at baseline and at one month, three months 
and six months after intervention was  511 +  135.52, 274.1 +  83.41, 207.2 +  39.52 and 
204.1 +  38.34, respectively; this difference was statistically significant (one-way ANOVA 
[d.f.=3]; Fisher F-value = 29.623; P=0.000)(Table 6). There were also significant differences 
between the mean CFT at  baseline (511 +  135.52 microns) and that at one month (274.1 +  
83.41 microns)(student `t’test [d.f.=18] = 4.7077; P [2-tailed]= 0.0002), between the baseline 
value and that at three months (207.2 +  39.52 microns) [student `t’test (d.f.=18) = 6.8055; 
P[2-tailed]= < 0.0001) and between the baseline value and that at six months (204.1 +  
38.34microns) [student `t’test (d.f.=18) = 6.890; P[2-tailed]= <0.0001)(Table 6). In this laser 
treated group there were also significant differences between the mean CFT at  one month 
and that at three months (student `t’test [d.f.=18] = 2.2921; P [2-tailed]= 0.0342) and  
between the mean CFT value at one month and that at six months [student `t’test (d.f.=18) = 
2.4113; P[2-tailed]=  0.0268); however, there was no significant difference between the mean 
CFT value at three months  and that at six months  [student `t’test (d.f.=18) = 0.1780; P[2-
tailed]= 0.8607)(Table 6).  
 
         Another outcome assessed was the visual gain, in terms of additional lines (compared to 
baseline) on the Snellen’s chart that could be read (Table 4, Figure 7). At one month after 
intervention, six (60%) of 10 eyes in the ranibizumab group, three (30%) of 10 eyes in the 
bevacizumab group and two (20%) of 10 eyes in the laser group showed a visual gain of ≥ 3  
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lines on Snellen’s chart (compared to baseline); these differences were statistically significant 
(chi square with Yates correction [d.f.=2] = 8.5; p = 0.02). At three months after intervention, 
six (60%) of 10 eyes in the ranibizumab group, two (20%) of 10 eyes in the bevacizumab 
group and two (20%) of 10 eyes in the laser group showed a visual gain of ≥ 3 lines on 
Snellen’s chart (compared to baseline); these differences approached statistical significance 
(chi square with Yates correction [d.f.=2] = 2.48; p = 0.08). At six months after intervention, 
six (60%) of 10 eyes in the ranibizumab group, four (40%) of 10 eyes in the bevacizumab 
group and two (20%) of 10 eyes in the laser group showed a visual gain of ≥ 3 lines on 
Snellen’s chart (compared to baseline); these differences approached statistical significance 
(chi square with Yates correction [d.f.=2] = 3.4; p = 0.06). 
 
An additional outcome evaluated was the mean percentage of improvement of BCVA at six 
months, in comparison with baseline BCVA, in the different study groups (Table 7). The 
mean percentage of improvement of BCVA at six months, when compared to baseline 
BCVA, was found to be (%) 313.6 ±   171.2 , 270.8 ±  178.2 and 191.9 ±    64.5  in the 
ranibizumab-treated, bevacizumab-treated and laser-treated eyes, respectively; these 
differences were not statistically significant across the three groups (one-way ANOVA 
[d.f.)=2, Fisher F-value= 1.745; P [2-tailed]= 0.194) (Table7). Similarly, no significant 
differences were observed in the mean percentage of improvement in BCVA between laser 
and bevacizumab groups (student `t’ [d.f.=18]= 1.3165; P [2-tailed]= 0.2045) and no 
significant differences were observed in the mean percentage of improvement in BCVA  
 
46 
 
 
between bevacizumab and ranibizumab groups (student `t’ [d.f.=18]= 0.5463; P [2-tailed]= 
0.5915). However, the difference between mean percentage of improvement in BCVA 
between laser and ranibizumab groups approached statistical significance (student `t’ 
[d.f.=18]= 2.09; P (2-tailed)= 0.0507).  
 
 An assessment was made of  the proportion of patients (eyes) showing >  200 percent 
improvement in best corrected visual acuity (calculated by comparing 6 month values with 
baseline values)  in the different study groups (Table 8); this worked out to ten (100%) of 10 
eyes in the ranibizumab-treated group, seven (70%) of 10 eyes in the bevacizumab-treated 
group and four (40%) of 10 eyes  in the laser –treated group; these differences were 
statistically significant (chi-square test with Yates’ correction [d. f. =2] = 8.58; P [2-tailed]= 
0.0346).  
 
          An additional outcome evaluated was the mean percentage of reduction in CFT at six 
months, in comparison with baseline CFT, in the different study groups (Table 7). The mean 
percentage of reduction of CFT at six months, when compared to baseline CFT, was found to 
be (%) 279.7 ± 60.53 , 239.2  ±  55.3 and 249.8 ±   42.9  in the ranibizumab-treated, 
bevacizumab-treated and laser-treated eyes, respectively; these differences were not 
statistically significant across the three groups (one-way ANOVA [d.f.]=2, Fisher F-value= 
1.545; P [2-tailed]= 0.231) (Table7). 
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 Similarly, no significant differences were observed in the mean percentage of reduction of 
CFT between laser and bevacizumab groups (student `t’ [d.f.=18]= 0.4789; P [2-tailed]= 
0.6378), between laser and ranibizumab groups(student `t’ (d.f.=18)= 1.2744; P (2-tailed)= 
0.2187) and between bevacizumab and ranibizumab groups (student `t’ [d.f.=18]= 1.5621; P 
[2-tailed]= 0.1357).  
 
 An assessment was made of  the proportion of patients (eyes) showing >  200 percent 
reduction in central foveal thickness (calculated by comparing 6 month values with baseline 
values)  in the different study groups (Table 9); this worked out to nine (90%) of 10 eyes in 
the ranibizumab-treated group, eight (80%) of 10 eyes in the bevacizumab-treated group and 
nine (90%) of  10 eyes in the laser – treated group; these differences were not statistically 
significant (chi-square test with Yates’ correction [d. f. =2] = 1.34; P [2-tailed] > 0.05).  
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DISCUSSION 
 
Branch retinal vein occlusion (BRVO) is the second most common cause of retinal pathology 
after diabetic retinopathy1,2. In most patients, macular edema is the predominant cause of 
visual loss although severe non-perfusion of perifoveal capillaries is an additional source of 
reduced vision7. Elevated intra ocular levels of VEGF have been demonstrated in eyes with 
BRVO and this has been linked to vascular leakage8,9. Thus there is a strong rationale for 
using VEGF antagonists in eyes with macular edema following BRVO. 
 
          The present study was a randomized prospective interventional study comparing 
intravitreal ranibizumab, intravitreal bevacizumab and laser photocoagulation for the 
treatment of macular edema following BRVO. Each treatment group had 10 patients (10 
eyes). There was no statistical differences between the three groups in age or gender 
distribution and in presence of associated systemic diseases (Table 1, 2 and 3). Thus for all 
practical purposes, the three groups were matched. All three interventions yielded  
improvement in visual acuity (Table 5) as well as reduction in CFT  (as assessed by 
OCT)(Table 6) although the amount and speed of improvement differed markedly in these 
groups. 
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   Both groups where intravitreal ranibizumab and intravitreal bevacizumab were used 
showed a rapid resolution of macular edema with improvement in visual acuity(Table 5). 
Other studies11-13 have also shown that blocking VEGF with intravitreal anti-VEGF agents 
has a rapid and beneficial effect on visual function. This effect has been attributed to the 
reduction in vascular leakage that is mediated by VEGF. 
 
         The largest study16 to date involving ranibizumab for macular edema following BRVO  
(BRAVO study) found that an intraocular injection of  0.3 or 0.5 mg of ranibizumab provided 
a rapid, effective treatment for macular edema due to BRVO. The BRAVO study utilized a 
monthly injection of ranibizumab for 6 months, with option of rescue laser beginning from 
three months if eligible. Rescue laser eligibility was defined as clearing of haemorrhage with 
visual acuity of <6/12 or CFT > 250 microns16. In the present study however, a different 
protocol was used. All patients received anti VEGF agents at the first visit, followed by laser 
after 7-10 days as soon as a clear view on FFA was obtained. This was performed for 2 
reasons: 
1) to reduce the number of intravitreal injections required, thereby reducing the cost 
of treatment and circumventing potential adverse effects of intravitreal injections; 
2) to provide permanent reduction in vascular leakage by photocoagulating areas of 
leakage as compared to the temporary effects of anti-VEGF agents. 
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The degree of improvement in visual acuity and reduction in CFT in the present study, where 
intravitreal ranibizumab was used (Table 7, 8, 9), was comparable to the BRAVO study 
thereby validating the efficacy of the  treatment protocol used in the present study. 
 
    Although several studies have found intravitreal bevacizumab to be effective in reducing 
macular edema secondary to BRVO11-13, it is believed that no study has compared the 
efficacy of intravitreal ranibizumab and bevacizumab. Intravitreal ranibizumab appeared 
more effective than bevacizumab  in terms of final visual outcome (Table 5) ,  and visual gain 
as Snellen lines at the one month, third month and sixth month follow-ups (Table 4). 
Similarly the reduction in central foveal thickness in ranibizumab treated patients, compared 
to bevacizumab and laser treated patients suggests that a larger sample size will produce a 
statistically significant outcome. The reason for the greater efficacy of ranibizumab is 
probably related to smaller molecular size, allowing rapid penetration through the retinal 
layers as well as greater affinity for VEGF established by ranibizumab59. 
 
Although laser is the current gold standard for treatment of  macular edema due to BRVO, 
the BVO study10 found a modest improvement in patients treated with laser 
photocoagulation. Laser treatment cannot be given to patients with fresh venous occlusions 
owing to retinal haemorrhages  and it takes several months for the haemorrhages to clear. 
During this time, severe retinal edema could compromise retinal cells leading to permanent 
structural damage. 
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     Both improvement in visual acuity and reduction in central foveal thickness appeared  to 
be better in eyes that had received intravitreal ranibizumab therapy as compared to eyes 
treated with laser alone during the entire study(Table 4, 5, 6, 7, 8, 9). Laser appears to have a 
definite role in treating macular edema due to BRVO as it produces a permanent stoppage of 
vascular leakage as compared to the temporary effects of intravitreal injections. Thus, use of 
laser could reduce need for repeated intravitreal injections. 
 
      No significant ocular or systemic side-effects were observed in patients who received 
intravitreal injections of ranibizumab or bevacizumab. The safety of anti VEGF agents has 
been documented in other studies also. However, any intravitreal injection follows a small 
but definite risk of complications such as retinal tears, endophthalmitis and cataract and it 
would seem wise to limit the number of intravitreal injections to the barest required. 
Moreover, when assessing the safety of a medication , the ‘rule of three’ should be kept in 
mind 63. This rule states that if none of the ‘n’ patients  has the adverse effect in question, 
then there can be a reasonable confidence interval (95%) that the true rate of this event in the 
population is no more than 3 in ‘n’ (3/n). Thus in the present study, where 20 patients 
received anti-VEGF agents (10 ranibizumab group and 10 bevacizumab group), the true rate 
of the adverse event in question in the population  is about 3/20 or 15%. Hence, more detailed 
studies on larger number of patients is needed to confirm the safety of these anti-VEGF 
agents. However, the results of the present study are certainly promising, since the confidence 
in the efficacy of a treatment or management approach is enhanced if the results are based on 
a prospective randomized trial as in the case of the present study64.  
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CONCLUSION 
  
               Branch retinal vein occlusion (BRVO) is the one of the most common cause of 
retinal pathology after diabetic retinopathy. In most patients, macular edema is the 
predominant cause of visual loss although severe non-perfusion of perifoveal capillaries is an 
additional source of reduced vision. Elevated intra-ocular levels of  VEGF have been 
demonstrated in eyes with BRVO and this has been linked to vascular leakage. Thus, there is 
a strong rationale for using VEGF antagonists such as ranibizumab and bevacizumab in eyes 
with macular edema following BRVO. 
             Although the effect of anti VEGF agents is very rapid and dramatic, the effect is 
short-lived and repeated injections are required which, in turn, increases the cost of treatment. 
If the permanent effects of laser (i.e. permanent stoppage of vascular leakage as compared to 
the temporary effects of intravitral injections) can be combined with the rapid (but 
temporary) effect of intravitreal injections of anti-VEGF agents, then it not only reduces the 
number of intravitreal injections but also reduces the financial burden of treatment, which is 
very important in developing countries like India. 
         In conclusion, both ranibizumab and bevacizumab treatment in macular edema due to 
BRVO result in gain in visual acuity and reduction in intraretinal thickness which occurs 
rapidly. However, these anti-VEGF agents should always be combined with a more 
permanent treatment such as laser photocoagulation, which would yield much better results 
than any single mode of treatment  alone. 
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SUMMARY 
 
Ranibizumab is a recently-described molecule that exhibits an antagonistic action on vascular 
endothelial growth factor (VEGF). Therefore, it is potentially useful in the management of 
macular edema that follows branch retinal vein occlusion (BRVO). The aim of the study 
described in this dissertation was to demonstrate the efficacy of ranibizumab (0.5 mg, 
intravitreal injection) over a six-month treatment period in eyes with macular edema due to 
BRVO. Primary measures of efficacy demonstrated during the study period were a) an 
improvement in mean best corrected visual acuity (BCVA) and b) a reduction in mean central 
foveal thickness (CFT) , as assessed by optical coherence tomography (OCT).  
 
This investigation was an open-label, prospective randomized interventional study which was 
performed at the retina clinic of a tertiary eye care facility in southern India over a period of 
12 months (1st June 2009 to 31st May 2010). Thirty patients (30 eyes), comprising 12 males 
and 18 females (age range 38 to 74 years), who presented with macular edema due to BRVO 
during the study period, who satisfied the inclusion criteria and who provided consent for 
participation, were enrolled in the study. Upon presentation (baseline) and after ensuring that 
all investigational requirements were satisfied, each patient was randomly assigned to one of 
three interventional groups, namely  ranibizumab, bevacizumab or laser. Thus, each 
interventional group consisted of 10 patients (10 eyes). 
 
 
54 
 
 
Patient demographics (age, gender, associated systemic diseases) and baseline ocular 
characteristics did not differ significantly across all the interventional groups. The mean age 
of the patients in the ranibizumab-treated, bevacizumab treated and laser-treated  groups was 
58.8 + 9.47 years (range 42 to 74), 58.4  + (SD) 8.55 years (range 38 to 68 years) and 57.0 +  
8.97 years (range 38 to 69 years), respectively; these differences were not statistically 
significant. Males comprised two (20%), six (60%) and four (40%) of the patients in the 
ranibizumab-treated, bevacizumab-treated and laser-treated groups, respectively (differences 
not statistically significant). In addition to macular edema,  29 (97%) of  the 30 study patients 
suffered from associated systemic diseases, namely hypertension alone (in 70%, 80% and 
70% of patients treated with ranibizumab, bevacizumab or laser, respectively), diabetes 
mellitus only (in 10% of ranibizumab-treated patients) and hypertension and diabetes mellitus 
(in 20%, 10% and 30% of patients treated with ranibizumab, bevacizumab or laser, 
respectively)(differences not statistically significant).  
 
The mean BCVA in the three interventional groups was assessed at baseline (presentation), 
and one month, three months and six months  after intervention. At baseline, there was no 
significant difference in the mean BCVA (decimals) between the ranibizumab, bevacizumab 
and laser  treatment groups (0.177 +  0.085, , 0.1663  + 0.103  and 0.21 + 0.12, respectively). 
The same trend was observed at each of the subsequent follow-up visits. At one month 
follow-up, the mean BCVA (in decimals) in the ranibizumab, bevacizumab and  laser 
treatment groups was 0.397 + 0.17, 0.365  + 0.23  and 0.38 + 0.28, respectively [differences  
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not statistically significant ]). At the third month follow-up, the mean BCVA (in decimals) in 
the ranibizumab, bevacizumab and laser treatment groups was 0.423 +  0.13, 0.337  + 0.23  
and 0.399 + 0.28 ,respectively (differences not statistically significant). At the sixth month 
follow-up, the mean BCVA (in decimals) in the ranibizumab, bevacizumab and laser 
treatment groups was 0.44 +  0.12, 0.38  + 0.21  and 0.399 + 0.28, respectively (differences 
not statistically significant). Thus, no significant inter-group differences were noted in BCVA 
achieved. 
 
Significant intragroup differences in BCVA values were noted in the ranibizumab group, 
both when the group was considered in its entirety (across all follow-up times) and between 
the baseline mean BCVA and that at one month, three month and sixth month follow-ups.  In 
this group, there were no significant differences between the mean BCVA values at one 
month versus three months, one month versus six months , and three months versus six 
months. No significant intragroup difference in BCVA values was observed when the 
bevacizumab group was considered in its entirety (across all follw-up times). However, 
significant differences were observed  between the mean BCVA at  baseline and that at one 
month,  three months and  six months. In this group, there were no significant differences 
between the mean BCVA values at one month versus three months, one month versus six 
months , and three months versus six months. Similarly, there was no  significant intragroup 
difference  when the laser group was considered in its entirety.  
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There was also no significant difference between the mean BCVA at  baseline and that at one 
month,  three months and six months.  
 
The mean CFT was also assessed in the three interventional groups at baseline (presentation), 
and one month, three month and six month follow-up visits. At baseline, the mean CFT (in 
microns) in the ranibizumab, bevacizumab and laser treatment groups (623.2 ± 328.04, 561.2 
±  187 and 511 +  135.52, respectively) did not differ significantly. The same trend was 
observed at each of the subsequent follow-up visits. At the one month follow-up visit, the 
mean CFT (in microns) in the ranibizumab, bevacizumab and laser treatment groups was 
236.6  ±  126.37, , 254.3 ±  106.9 and 274.1 +  83.41 (differences not statistically significant). 
At the third month follow-up, the mean CFT(in microns) in the ranibizumab, bevacizumab 
and laser treatment group was  216.0  ±  69.12, 284.7 ±  130.4 and 207.2 +  39.52, 
respectively(differences not statistically significant). At six months following intervention, 
the mean CFT (in microns) in the ranibizumab,  bevacizumab and laser treatment groups was 
216.2  ±  63.85, 241.0 ±    88.9  and 204.1 +  38.34  respectively (differences not statistically 
significant). Thus, no significant inter-group differences were noted in the mean CFT.  
 
Significant intragroup differences in mean CFT were noted when each of the treatment 
groups was considered in its entirety (across all follow-up times). Significant intragroup 
differences in mean CFT values were noted in the ranibizumab, bevacizumab and laser 
treatment groups, both when each  group was considered in its entirety (across all follow-up  
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times) and between the baseline mean CFT value and that at one month, three month and 
sixth month follow-ups.  There were also significant differences between the mean CFT at  
one month and that at three months and six months in the laser treatment group. However, 
there was no significant difference between the mean CFT value at three months  and that at 
six months  in the laser treatment group, and also no significant differences between mean 
CFT values at one month , three months and six months in the ranibizumab-treated and 
bevacizumab-treated groups.  
 
           Visual gain in terms of additional lines (compared to baseline) on the Snellen’s chart 
that could be read was assessed at baseline and at six months (Table 4, Figure 7). At one 
month after intervention, six (60%) of 10 eyes in the ranibizumab group, three (30%) of 10 
eyes in the bevacizumab group and two (20%) of 10 eyes in the laser group showed a visual 
gain of ≥ 3 lines on Snellen’s chart (compared to baseline); these differences were 
statistically significant . At three months after intervention, six (60%) of 10 eyes in the 
ranibizumab group, two (20%) of 10 eyes in the bevacizumab group and two (20%) of 10 
eyes in the laser group showed a visual gain of ≥ 3 lines on Snellen’s chart (compared to 
baseline); these differences approached statistical significance . At six months after 
intervention, six (60%) of 10 eyes in the ranibizumab group, four (40%) of 10 eyes in the 
bevacizumab group and two (20%) of 10 eyes in the laser group showed a visual gain of ≥ 3 
lines on Snellen’s chart (compared to baseline); these differences approached statistical 
significance. 
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There were no significant differences between the ranibizumab-treated, bevacizumab-treated 
and laser-treated groups when the mean percentage of improvement of BCVA at six months, 
in comparison with baseline BCVA, was assessed. However, the difference between mean 
percentage of improvement in BCVA between laser and ranibizumab groups approached 
statistical significance.  
 
An assessment was made of  the proportion of patients (eyes) showing >  200 percent 
improvement in BCVA (calculated by comparing 6 month values with baseline values)  in the 
different study groups ; this worked out to all 10 eyes (100%) in the ranibizumab –treated 
group, seven (70%) of 10 eyes in the bevacizumab-treated group and four (40%) of 10 eyes 
in the laser-treated group; these differences were statistically significant.  
 
There was no significant differences between the study groups in the mean percentage of 
reduction of  CFT at six months, in comparison with baseline CFT. Similarly, no significant 
differences were observed in the mean percentage of reduction of CFT between laser and 
bevacizumab groups, between laser and ranibizumab groups and between bevacizumab and 
ranibizumab groups.   
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An assessment was made of  the proportion of patients (eyes) showing >  200 percent 
reduction in central foveal thickness (calculated by comparing 6 month values with baseline 
values)  in the different study groups; this worked out to nine (90%) of 10 eyes in the laser-
treated group, eight (80%) of 10 eyes in the bevacizumab-treated group and nine (90%) of  10 
eyes in the ranibizumab – treated group; these differences were not statistically significant.  
 
Overall, intravitreal ranibizumab appeared to be more efficacious than bevacizumab in terms 
of final visual outcome and reduction in CFT. Although these differences were not 
statistically significant, the differences were notable enough to suggest that a larger sample 
size would yield statistically significant differences in outcome. A possible reason for the 
putative greater efficacy of ranibizumab is possibly related to its smaller molecular size, 
allowing rapid penetration through the retinal layers as well as greater affinity for VEGF.  
 
It was also observed that both improvement in visual acuity and reduction in CFT were more 
notable in eyes that had received intravitreal anti-VEGF therapy (ranibizumab or 
bevacizumab) than in eyes that had received laser alone. However, laser appears to have a 
definite role in treating macular edema arising out of BRVO as it produces a permanent 
stoppage of vascular leakage, compared to the temporary effects of intravitreal injections. 
Thus, use of laser could reduce the need for repeated intravitreal injections.  
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                                                              RANIBIZUMAB  GROUP 
 
 
 
MR NO. Age Sex Asso disease BCVA (0) CFT (0) BCVA (1m) CFT (1m) BCVA (3m) CFT (3m) BCVA (6m) CFT (6m) Dose
767636 60 F HT 0.25 615 0.5 191 0.5 216 0.5 255 1
562304 63 F HT 0.25 396 0.5 220 0.5 221 0.5 205 1
638301 74 M HT 0.1 384 0.16 123 0.5 156 0.5 160 1
745383 58 F HT/DM 0.05 1527 0.25 583 0.25 404 0.25 383 1
749703 52 F HT 0.25 500 0.66 175 0.5 181 0.5 184 1
757956 50 F HT 0.16 634 0.33 184 0.33 179 0.33 180 1
755804 42 F HT 0.05 564 0.25 205 0.33 183 0.33 180 1
748654 55 F HT/DM 0.25 511 0.66 220 0.66 214 0.66 210 1
607917 66 F HT 0.16 570 0.33 215 0.33 205 0.33 201 1
754311 68 M DM 0.25 531 0.33 250 0.33 201 0.5 204 1
MEAN 58.8 0.177 623.2 0.397 236.6 0.423 216 0.44 216.2 1
 
                                                   BEVACIZUMAB GROUP 
 
 
MR NO. Age Sex Asso disease BCVA (0) CFT (0) BCVA (1M) CFT(1M) BCVA(3M) CFT(3M) BCVA (6M) CFT (6M) DOSE
750670 59 M HT/DM 0.16 343 0.5 190 0.16 527 0.5 221 2
756364 53 F HT 0.033 558 0.1 350 0.16 289 0.25 189 1
754145 63 M none 0.16 645 0.25 230 0.25 244 0.25 240 1
715979 65 F HT 0.1 703 0.25 509 0.25 480 0.25 447 1
737718 68 M HT 0.33 576 0.66 200 0.66 210 0.66 220 1
749038 60 F HT 0.1 378 0.16 160 0.16 165 0.16 170 1
734730 54 M HT 0.1 648 0.25 202 0.25 200 0.25 202 1
784728 64 M HT 0.33 398 0.66 197 0.66 167 0.66 170 1
761620 38 M HT 0.25 414 0.66 197 0.66 200 0.66 201 1
777358 60 F HT 0.1 949 0.16 308 0.16 365 0.16 350 1
Mean= 58.4 0.1663 561.2 0.365 254.3 0.337 284.7 0.38 241 1.1
                                                       LASER GROUP 
 
 
MR NO. Age Sex Asso disease BCVA(0) CFT (0) BCVA (1m) CFT (1m) BCVA (3m) CFT (3m) BCVA (6m) CFT (6m) LASER
718470 65 M HTN 0.33 626 0.5 305 0.5 199 0.5 193 1
756760 60 M HT/DM 0.33 388 1 179 1 180 1 164 1
730002 69 F HT 0.33 410 0.33 252 0.5 170 0.5 164 1
727875 55 F HT 0.16 405 0.33 230 0.33 148 0.33 179 1
745938 57 F HT/DM 0.083 576 0.1 367 0.1 280 0.1 250 1
723630 38 F HT 0.083 474 0.1 221 0.16 208 0.16 166 1
721118 52 M HT/DM 0.25 648 0.33 428 0.33 220 0.33 250 1
744648 65 F HT 0.1 751 0.16 343 0.16 243 0.16 256 1
730243 59 M HT 0.33 328 0.66 180 0.66 184 0.66 189 1
715065 50 F HT 0.083 504 0.25 236 0.25 240 0.25 230 1
Mean = 57 0.2079 511 0.376 274.1 0.399 207.2 0.399 204.1 1
                                                       LASER GROUP 
 
 
MR NO. Age Sex Asso disease BCVA(0) CFT (0) BCVA (1m) CFT (1m) BCVA (3m) CFT (3m) BCVA (6m) CFT (6m) LASER
718470 65 M HTN 0.33 626 0.5 305 0.5 199 0.5 193 1
756760 60 M HT/DM 0.33 388 1 179 1 180 1 164 1
730002 69 F HT 0.33 410 0.33 252 0.5 170 0.5 164 1
727875 55 F HT 0.16 405 0.33 230 0.33 148 0.33 179 1
745938 57 F HT/DM 0.083 576 0.1 367 0.1 280 0.1 250 1
723630 38 F HT 0.083 474 0.1 221 0.16 208 0.16 166 1
721118 52 M HT/DM 0.25 648 0.33 428 0.33 220 0.33 250 1
744648 65 F HT 0.1 751 0.16 343 0.16 243 0.16 256 1
730243 59 M HT 0.33 328 0.66 180 0.66 184 0.66 189 1
715065 50 F HT 0.083 504 0.25 236 0.25 240 0.25 230 1
Mean = 57 0.2079 511 0.376 274.1 0.399 207.2 0.399 204.1 1
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